Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2014

View Archived Issues

World MS Day: Recent innovations in stem cell therapies, small molecules and biomarkers

Tufts anti-PAR2 pepducin targeted at pulmonary hypertension

AZTherapies initiates trial of combination therapy in Alzheimer's disease

Abzena formed following PolyTherics and Antitope merger

Johnson & Johnson updates on its Medical Devices and Diagnostics business

BioInvent sells back ADC-1013 rights to Alligator Bioscience

Phase IIb study tests non-viral gene transfer for cystic fibrosis

Animal model of hypertriglyceridemia developed in zebrafish

Discovery and characterization of a small-molecule modulator of EBI2

Human iPS-endothelial cells overexpressing IL-8 receptors inhibit vascular injury

Amakem reports novel ROCK inhibitors

Bristol-Myers Squibb patents new HCV inhibitors

Novel PDE10A inhibitors disclosed by Allergan and Diaxonhit

Bionure's BN-201 promotes myelination in cell-culture assay

Cel-Sci expands phase III study of Multikine to new U.S. site

FDA grants orphan drug status to SAR-650984 for cancer

Norwegian investigators disclose new fusion proteins for allergic diseases

Daiichi Sankyo launches Efient in Japan for patients undergoing PCI

LG Life Sciences patents new FFA4 receptor agonists

Wellcome Trust grant supports Calibr's development of immunotherapy for prostate cancer

FDA issues complete response letter for MoxDuo

InterMune resubmits pirfenidone NDA to the FDA

FDA grants orphan drug designation to Advaxis' ADXS-cHER2 for osteosarcoma

Ganymed reports results from phase IIa gastroesophageal cancer trial

Daiichi Sankyo gains rights to lurasidone in four South American countries

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.